DESTINY-Breast02

NCT03523585 📎

Regimen

Experimental
Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks.
Control
Treatment of physician's choice (trastuzumab + capecitabine or lapatinib + capecitabine).

Population

HER2-positive metastatic breast cancer with progression after prior T-DM1.

Key finding

DESTINY-Breast02 provided the randomized confirmation (missing from DB-01) that T-DXd beats physician's choice after T-DM1. Reinforces T-DXd as preferred therapy across HER2+ treatment sequence.

Source: PMID 37086745

Timeline

  • Publication: 2023 May 27

Guideline citations

  • NCCN BREAST